Vitamin D supplementation may help offset damaging bone loss that occurs in some people who take canagliflozin, a commonly prescribed diabetes drug. Researchers will present their work this week at the American Physiological Society (APS) and American Society for Nephrology Control of Renal Function in Health and Disease conference in Charlottesville, Virginia.
A class of diabetes drug called SGLT2 inhibitors has been shown to slow the progression of diabetes-related kidney disease and is increasingly being considered as a first-line treatment option for people with diabetes who have a high risk for developing kidney and heart disease. However, some studies have found SGLT inhibitors to negatively affect bone health by accelerating loss of bone mineral density and hampering the activation of vitamin D by the body. The combination of these events can increase the risk of bone fracture. Researchers from the University of Maryland School of Medicine hypothesize that people who already have lower-than-normal levels of vitamin D have an even higher risk of bone loss and possible fracture when taking SGLT2 inhibitors.
The research team studied adults from an Old Order Amish community in Lancaster, Pennsylvania. The researchers explained that they chose this population due to the availability of extensive genetic sequencing data, but also because, unlike commercially processed milk, the farm-fresh milk many people in the Amish community drink is not fortified with vitamin D. Therefore, it is more likely that Amish people consume less vitamin D from their diet than the general population in the U.S.
The volunteers-;some of whom were found to have preexisting low vitamin D levels-;took canagliflozin, an SGLT2 inhibitor, for five days before and after they were given vitamin D supplements. The researchers found that in people who were vitamin D-deficient, canagliflozin led to a significant decrease (31%) in the levels of a metabolite used to measure vitamin D levels, but a much smaller decrease (7%) in those with normal vitamin D status. The supplements then boosted levels of parathyroid hormone, which regulates calcium levels in the blood and vitamin D levels in the bones.
The research team explained that short-term study of vitamin D supplements to counter the adverse effects of SGLT2 inhibitors on bone health shows promising results, but more research is needed.
Longer term follow-up will be required to determine whether this accelerated loss of bone mineral density will eventually translate into an increased risk of bone fracture over the course of 10–20 years of chronic therapy. Accordingly, we recommend that patients and physicians consider the possibility of taking vitamin D supplements to restore normal vitamin D status in vitamin D-deficient patients receiving (or who will receive) SGLT2 inhibitors."
Zhinous Yazdi, MD, first author of the study